Imatinib, also known by its brand name Gleevec, is a tyrosine kinase inhibitor. It was developed to target the abnormal protein product of the BCR-ABL gene fusion, which is a characteristic of CML. This fusion protein results from a chromosomal translocation known as the Philadelphia chromosome.
